Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
Otonomy, Inc. (Nasdaq: OTIC) has announced the presentation of preclinical data for OTO-825, a gene therapy for congenital hearing loss, at the American Society of Gene & Cell Therapy (ASGCT) Meeting from May 16-19 in Washington, DC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Otonomy, Inc. (Nasdaq: OTIC) has announced the presentation of preclinical data for OTO-825, a gene therapy for congenital hearing loss, at the American Society of Gene & Cell Therapy (ASGCT) Meeting from May 16-19 in Washington, DC. Dr. Phillip Uribe will present findings on May 19 at 11:15 a.m. ET, focusing on OTO-825's development for GJB2 deficiency. Otonomy specializes in innovative therapeutics for neurotology, particularly aimed at addressing hearing loss and tinnitus through advanced drug delivery technology.
Positive
- Presentation of promising preclinical data for OTO-825 at a prominent conference.
- Focused on significant medical needs in congenital hearing loss, expanding Otonomy's product pipeline.
Negative
- None.
Details
News Market Reaction – OTIC
The recorded move for OTIC in the trading session of this news was -3.91%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the presentation of preclinical data for OTO-825 at the upcoming American Society of Gene & Cell Therapy (ASGCT) Meeting being held May 16-19 in Washington, DC.
Dr. Phillip Uribe from Otonomy will be making a podium presentation entitled “Preclinical Development of an AAV-based Gene Therapy (OTO-825) for Congenital Hearing Loss Due to GJB2 Deficiency” beginning at 11:15 a.m. ET on May 19. This presentation is included in the “Breakthroughs in Neuromuscular and Hearing Disorders” session of the ASGCT meeting.
About Otonomy
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.
Contacts:
Media Inquiries:
Spectrum Science
Lauren Benton
Senior Account Executive
212.899.9731
lbenton@spectrumscience.com
Investor Inquiries:
Westwicke ICR
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.